Q-omics provides the consensus-scored RAD17 profile across patient tissues and cancer cell-line models. RAD17 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAD17 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, RAD17 RNA expression shows 20,747 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, THCA, and ACC as cancer lineages where RAD17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAD17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAD17 survival associations across molecular data types. RAD17 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAD17 RNA expression–survival associations across cancer types. High RAD17 expression shows unfavorable associations in KICH, LIHC and LGG, but favorable associations in KIRC, READ and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAD17 RNA expression.
This table summarizes RAD17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for RAD17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAD17 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, HNSC, LUAD and CHOL. The THCA box plot shows higher RAD17 RNA expression in normal versus tumor tissue (log2 FC = −0.584, t-test p < 0.001).
This table shows molecular features associated with RAD17 in patient tissues and cancer cell lines. In patient samples, RAD17 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RAD17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
